Compounds > niacinamide

niacinamide and fluorodeoxyglucose f18

niacinamide has been researched along with fluorodeoxyglucose f18 in 23 studies

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (17.39)29.6817
2010's18 (78.26)24.3611
2020's1 (4.35)2.80

Authors

AuthorsStudies
Corstens, FH; de Geus-Oei, LF; Kaanders, JH; Oyen, WJ; Pop, LA1
Araki, K; Ebi, H; Kawada, K; Kim, YI; Kitagawa, K; Minami, H; Mukai, H; Nakajima, H; Nakajima, K; Tahara, M1
Brouwers, AH; Hospers, GA; Mulder, NH; Siemerink, EJ1
Boijsen, M; Lundstam, S; Lyrdal, D; Stierner, U; Suurküla, M1
Aide, N; Denoyer, D; Dorow, DS; Greguric, I; Hicks, RJ; Katsifis, A; Neels, OC; Roselt, P; Taylor, SR1
Ambrosini, V; D'Errico-Grigioni, A; Fanti, S; Fini, M; Franchi, R; Giavaresi, G; Malvi, D; Nanni, C; Quarta, C; Torricelli, P; Zinzani, PL1
El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L1
Caponigro, F; Ciarmiello, A; Milano, A; Perri, F1
Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, JD; Lee, JH; Park, JY; Seo, HJ1
Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M1
Cowey, CL; Gohil, H; Khandani, AH; Moore, DT; Rathmell, WK1
Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D1
Camera, L; Colao, A; Del Prete, M; Esposito, R; Faggiano, A; Fonti, R; Marotta, V; Palmieri, G; Ramundo, V; Salvatore, M; Vitale, M1
Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A1
Banzo, I; Carril, JM; Martínez-Rodríguez, I1
Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M1
Chen, JG; Huang, JG; Jiang, FC; Liang, X; Liu, JM; Long, LH; Luo, H; Rao, J; Shen, ZC; Wang, F; Wu, PF; Xie, QG; Zhou, J1
Abrantes, AM; Botelho, MF; Brito, AF; Casalta-Lopes, JE; Gonçalves, AC; Laranjo, M; Mamede, AC; Ribeiro, M; Sarmento-Ribeiro, AB; Tralhão, JG1
Ameye, L; Delaunoit, T; Deleporte, A; Demolin, G; Flamen, P; Garcia, C; Gauthier, N; Guiot, T; Hendlisz, A; Holbrechts, S; Lhommel, R; Maréchal, R; Van den Eynde, M; Vierasu, I; Woff, E1
Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M1
Bao, B; Delaney, J; Groves, K; Ho, G; Kossodo, S; Morin, J; Narayanan, N; Peterson, JD; Rajopadhye, M; Tseng, JC; Zhang, J1
Bae, SH; Choi, JY; Hwang, S; Jang, JW; Park, HL; Song, MJ; Sung, PS; Yang, K; Yoo, IR; Yoon, SK1
Barentsz, JO; Gotthardt, M; Israël, B; Janssen, MJR; Mehra, N; Mulders, PFA; Muselaers, CHJ; Nagarajah, J; Privé, BM; Schilham, MGM; Sedelaar, M; van Oort, IM; Verzijlbergen, F; Witjes, JA; Zámecnik, P1

Reviews

1 review(s) available for niacinamide and fluorodeoxyglucose f18

ArticleYear
Targeted-therapy and imaging response: a new paradigm for clinical evaluation?
    Reviews on recent clinical trials, 2011, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2011

Trials

6 trial(s) available for niacinamide and fluorodeoxyglucose f18

ArticleYear
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
    Cancer science, 2008, Volume: 99, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Sorafenib

2008
Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
    Nuclear medicine communications, 2009, Volume: 30, Issue:7

    Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2009
Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
    Nuclear medicine communications, 2012, Volume: 33, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biological Transport; Carcinoma, Renal Cell; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Safety; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2012
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
    Clinical lung cancer, 2013, Volume: 14, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed

2013
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
    Head & neck, 2016, Volume: 38, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult

2016
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome

2016

Other Studies

16 other study(ies) available for niacinamide and fluorodeoxyglucose f18

ArticleYear
Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2006, Volume: 80, Issue:1

    Topics: Aged; Aged, 80 and over; Carbon; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Niacinamide; Oxygen; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted

2006
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
    The oncologist, 2008, Volume: 13, Issue:6

    Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib

2008
High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:3

    Topics: Animals; Autoradiography; Cell Line, Tumor; Cell Transformation, Neoplastic; Contrast Media; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Kidney; Melanins; Melanoma; Mice; Neoplasm Metastasis; Niacinamide; Positron-Emission Tomography; Pyridines; Substrate Specificity; Tomography, X-Ray Computed; Transplantation, Homologous; Whole Body Imaging

2010
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2010, Volume: 54, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lymphoma; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Pyridines; Radiopharmaceuticals; Sorafenib; Treatment Outcome

2010
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
    International journal of oncology, 2011, Volume: 39, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2011
Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult

2011
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
    BMC cancer, 2012, May-02, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome

2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed

2012
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
    Clinical endocrinology, 2013, Volume: 78, Issue:5

    Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome

2013
Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy.
    Endocrine, 2013, Volume: 44, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2013
ST09, a Novel Thioester Derivative of Tacrine, Alleviates Cognitive Deficits and Enhances Glucose Metabolism in Vascular Dementia Rats.
    CNS neuroscience & therapeutics, 2016, Volume: 22, Issue:3

    Topics: Acetylcholinesterase; Animals; Apoptosis; Cell Line, Transformed; Cerebral Cortex; Cognition Disorders; Dementia, Vascular; Disease Models, Animal; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Fluorodeoxyglucose F18; Glucose; Hippocampus; In Vitro Techniques; Male; Maze Learning; Niacinamide; Nootropic Agents; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Tacrine

2016
New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.
    Nutrition and cancer, 2016, Volume: 68, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Quercetin; Sorafenib; Tumor Suppressor Protein p53

2016
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib

2017
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorodeoxyglucose F18; Humans; Mice, Transgenic; Molecular Imaging; Neoplasm Transplantation; Niacinamide; Optical Imaging; Phenylurea Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Random Allocation; Receptors, Bombesin; Receptors, Transferrin; Sorafenib; Treatment Outcome; Tumor Burden

2017
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:3

    Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sorafenib; Treatment Outcome

2018
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology.
    Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:2

    Topics: Aged; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Multiparametric Magnetic Resonance Imaging; Niacinamide; Oligopeptides; Positron Emission Tomography Computed Tomography; Prognosis; Prostatectomy; Prostatic Neoplasms; Radiopharmaceuticals; Retrospective Studies

2021